About CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (ST3GAL4) is a protein
from Homo sapiens identified by UniProt accession
Q11206, 333 residues long.
MolForge cross-references it against 0 known binders and
276 disease associations.
Target properties
| Protein name | CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 |
| UniProt accession | Q11206 |
| Gene | ST3GAL4 |
| Organism | Homo sapiens |
| Length | 333 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (276)
Diseases linked to this target (Open Targets).
- alkaline phosphatase measurement · score 0.49
- mean platelet volume · score 0.47
- platelet count · score 0.47
- COVID-19 · score 0.46
- blood protein measurement · score 0.46
- low density lipoprotein cholesterol measurement · score 0.46
- total cholesterol measurement · score 0.44
- body height · score 0.43
- e-selectin measurement · score 0.42
- high density lipoprotein cholesterol measurement · score 0.40
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q11206-F1 | alphafold | PREDICTED | 89.88 | — |
Amino-acid sequence (333 residues)
MVSKSRWKLL AMLALVLVVM VWYSISREDR YIELFYFPIP EKKEPCLQGE AESKASKLFG NYSRDQPIFL RLEDYFWVKT PSAYELPYGT KGSEDLLLRV LAITSSSIPK NIQSLRCRRC VVVGNGHRLR NSSLGDAINK YDVVIRLNNA PVAGYEGDVG SKTTMRLFYP ESAHFDPKVE NNPDTLLVLV AFKAMDFHWI ETILSDKKRV RKGFWKQPPL IWDVNPKQIR ILNPFFMEIA ADKLLSLPMQ QPRKIKQKPT TGLLAITLAL HLCDLVHIAG FGYPDAYNKK QTIHYYEQIT LKSMAGSGHN VSQEALAIKR MLEMGAIKNL TSF
Explore CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets